This guide provides practical, evidence-based information that first responder agencies, their partners, and communities can use to implement or expand practices and programs for linking people to substance use services.

This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This TIP supports learning about the key aspects, functions, and uses of Peer Support Services (PSS) in recovery from problematic substance use, which will help providers, supervisors, and administrators in SUD treatment programs better understand and respond to these changes.

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.

The goal of this guide is to review the literature on treating substance misuse and substance use disorders in the context of first-episode psychosis, distill the research into recommendations for practice, and provide examples of the ways that these recommendations can be implemented by first-episode psychosis treatment programs.

This guide focuses on using medication-assisted treatment for opioid use disorder in jails and prisons and during the reentry process when justice-involved persons return to the community. It provides an overview of policies and evidence-based practices that reduce the risk of overdose and relapse.

This guide examines a wide range of evidence-based practices for screening and assessment of people in the justice system who have co-occurring mental and substance use disorders.

The Rx Pain Medications, Know the Options, Get the Facts is a series of 13 fact sheets designed to increase awareness of the risks associated with prescription opioid use and misuse, as well as to educate patients who are prescribed opioids for pain about the risks and to provide resources on methods for alternative pain management.

This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD

Zero Suicide operationalizes the core components necessary for health care systems to transform suicide care into seven elements. Within each element section, find a description of what each element is, why it is necessary to Zero Suicide implementation, a summary of supporting research, and key readings and tools. Use the navigation bar that appears at the top of each element page to jump between sections.

This guide discusses the challenges in care transitions and the need for better care practices and care coordination from inpatient to outpatient behavioral health care, and presents feasible, evidence-based practices that health systems and providers can take to improve patient connection and safety during inpatient to outpatient transition, and provides recommendations specific to both inpatient and outpatient settings.

This Harm Reduction Coalition (HRC) manual outlines the process of developing an Overdose Prevention and Education Program, with or without a take-home naloxone component. Such a program may be integrated into existing services for people affected by substance abuse, including shelter and supportive housing agencies, treatment programs, parent and student groups, and communities at-large.

This guide from the American Society of Addiction Medicine (ASAM) includes information on assessment, treatment overview (including treatment plans, patient participation, and counseling), and all the medications available to treat opioid use and overdose. It also provides links to find a provider and support groups for patients and families.

This report provides behavioral health professionals, researchers, policymakers and other audiences with a comprehensive research overview and accurate information about effective and ineffective therapeutic practices related to youth of diverse sexual orientation and gender identity.